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Abstract: Background: Cholinesterase inhibitors and glu-
tamate blockers are commonly used for the treatment of 
cognitive impairment in Alzheimer’s disease. The aim 
was to evaluate the effects of rivastigmine and meman-
tine alone or in combination in rats with scopolamine-im-
paired memory. 
Method: 5 groups of rats were used: control, scopolamine 
(model), model with rivastigmine, model with memantine, 
and model with both drugs. Active avoidance test was per-
formed and the number of conditioned responses, uncon-
ditioned responses and intertrial crossing were recorded. 
Passive avoidance tests step-through with criteria latency 
of reaction 180 s in the light chamber and step-down with 
criteria latency of reaction 60 s on the platform were done. 
Results: Control rats learned the task and kept it on 
memory tests. Scopolamine treated rats failed to perform 
it. The rivastigmine, memantine and its combination 
groups showed increased CRs during learning and 
memory retention tests. In both passive avoidance tests 
an increased latency of reaction was observed in the drug 
treated groups. 
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Effects of rivastigmine and memantine alone and 
in combination on learning and memory in rats 
with scopolamine-induced amnesia
Conclusion: The combination of both drugs rivastigmine 
and memantine is more effective than the use of the single 
drug in cognitive impaired rats. Cholinesterase inhibitors 
and NMDA blockers may be combined in the treatment of 
different kind of dementias. 
Keywords: rivastigmine, memantine, drug combination, 
scopolamine model, rats.
1  Introduction
Of the five drugs that have been approved for symptomatic 
treatment of Alzheimer’s disease (AD), (tacrine, donepe-
zil, rivastigmine, galantamine and memantine), most act 
via the inhibition of acetylcholinesterase (AChE) or butyr-
ilcholinesterase (BuChE). 
Rivastigmine, a carbamate derivative of physostig-
mine, is unique in blocking AChE. It induces the attach-
ment of a carbamyl residue instead of performing the usual 
microsomal activity. Rivastigmine is therefore classified as 
a pseudo-irreversible inhibitor of AChE and BuChE [1].
The changes in acethylcholine (ACh) levels positively 
modulate glutamatergic function in animal models [2]. 
Memantine is a non-competitive NMDA glutamate recep-
tor channel inhibitor that binds to the disocilpine site [3]. 
NMDA receptors play a unique and vital role in subcellular 
signaling. Calcium influx through NMDA receptors initi-
ates signaling cascades important for both synaptic plas-
ticity and cell survival; however, over-activation of these 
receptors leads to toxicity and cell death. More specifically, 
it has been found, that NMDA receptors located at the 
synapse stimulate cell survival pathways, while extra-syn-
aptic receptors signal for cell death [4]. This interplay 
between synaptic and extra-synaptic NMDA receptors 
has been studied exclusively in cortical and hippocam-
pal neurons [5]. A deficit in NMDA receptor-dependent 
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neocortical plasticity has been found in patients with 
AD and transgenic rodents [6]. Synaptic scaling is a form 
of synaptic plasticity, that involves NMDA receptors and 
tends to restore neuronal activity to baseline levels was 
described by Watt et al, [7] and Turrigiano et al, [8]. Diffuse 
synaptic loss in AD should cause a compensatory increase 
(scaling) in the excitability of adjacent healthy neurons by 
increasing presynaptic glutamate release [9] and postsyn-
aptic receptor density [10]. Memantine’s inhibitory ability 
has been shown to significantly improve behavioral symp-
toms of AD, and is currently used for treatment of moder-
ate to severe AD [5]. 
The hypothesis that a combination of cholinergic and 
glutamanergic intervention could potentially provide a 
more effective therapy for AD. It has been suggested that 
the specific combination of an AChE inhibitor and the 
NMDA receptor inhibitor memantine might yield a syner-
gistic effect [11].
The aim of this study was to evaluate and compare 
the effects of rivastigmine or memantine alone or in com-
bination of the two, on rats with scopolamine-impaired 
memory.
2  Experimental procedures
All experiments were carried out according to the 
guidelines for the use of laboratory animals in EU and 
Bulgaria. Permission for the study was obtained by the 
Bulgarian Food Safety Agency No73/03.12.2012 and the 
Ethics Committee of the Medical University Plovdiv 
No3/05.07.2013.  
2.1  Chemicals
Memantine hydrochloride (Sigma)
Rivastigmine tartrate (Aldrich)
(-) Scopolamine hydrochloride (Sigma)
2.2  Animals
This study used 40 male Wistar rats with body weights of 
180-220g, divided into 5 groups (n=8). The animals were 
kept under standard laboratory conditions in an 08.00 – 
20.00 h light/dark cycle and were provided with food and 
water ad libitum. Groups were divided according to the 
administered treatments, as follows: 1) saline 0.1 ml/100g 
b.w. i.p. + saline 0.1 ml/100g b.w. p.o.; 2) scopolamine 1mg/
kg i.p. + saline 0.1 ml/100g b.w. p.o.; 3) scopolamine 1mg/
kg i.p. + rivastigmine 2 mg/kg p.o.; 4) scopolamine 1mg/kg 
i.p. + memantine 10 mg/kg p.o. and 5) scopolamine 1mg/
kg i.p. + rivastigmine 2 mg/kg p.o. + memantine 10/mg/
kg p.o. Substances were administered once daily for the 
duration of the experiment, 60 minutes before testing.
We used the effective doses of rivastigmine and 
memantine, improving effects on learning and memory 
processes in our preliminary experiments on naïve rats. 
Scopolamine was used as a model of impaired learning 
and memory in a dose, effective in our experiments study-
ing other cholinesterase inhibitors.
2.3  Behavioral tests
2.3.1  Active avoidance testing:
An automatic reflex conditioner for an active avoidance 
“shuttle box” (Ugo Basile, Italy) was used. The rats were 
placed into one of the chambers. Learning sessions were 
performed daily over 5 consecutive days. Each session 
consisted of 30 trials with the following parameters: 6s 
light and buzzer (670 Hz and 70 dB), 3s 0.4 mA foot shock, 
12s pause. A memory retention session was performed 
7 days after the last learning session (12th day) with the 
same parameters, but with the absence of a foot shock. 
The following parameters were recorded automatically: 1 
– number of conditioned responses (CR; avoidances); 2 – 
number of unconditioned responses (UCR; escapes from 
foot shock); 3 - number of intertrial crossings.
2.3.2  Passive avoidance testing (two passive avoidance 
tests were used):
An automatic set-up for a passive avoidance “step-
through” test (Ugo Basile, Italy) was used in a wire cage 
with 2 separate light and dark compartments. The rat was 
placed into the light chamber. The test parameters were as 
follows: door closed for 6s, door opened to allow entry into 
darkened chamber for 12s, 9 sec later 0.4mA foot shock 
and door closed. Learning sessions were performed over 
2 consecutive days, a short memory retention session was 
performed 24 hours later (3rd day), and a long memory 
retention session was performed on the 10th day. Memory 
retention tests were performed using the same parame-
ters, except for the absence of a foot shock. Sessions con-
sisted of 3 trials separated by 30 minute intervals. The 
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learning criterion used was a latency of reaction of 180 ± 2 
seconds staying in the light chamber.
An automatic set-up for a passive avoidance “step-
down” test (Ugo Basile, Italy) was used in a wire-floor 
single cage with a round central plastic platform. The rat 
was placed gently on the plastic platform. Learning ses-
sions consisted of 2 trials separated by a 60 minute inter-
val.  During each trial, electrical stimulation (0.4mA) was 
delivered to the wire floor for a duration of 10 s when the 
animal step down from the platform. Learning sessions 
were performed over 2 consecutive days, a short memory 
retention session was performed 24 hours later (3rd day), 
and a long memory retention session was performed on 
the 7th day. Memory retention tests were performed using 
the same parameters, but with the absence of a foot shock. 
A latency of reaction of 60 s (the rat was required to remain 
with all 4 paws on the platform for more than 60 s) was 
used as a criterion for learning and retention.
2.4  Statistical analysis
All observed parameters were expressed as means ± 
S.E.M. for each group. The comparison between groups 
was made using the repetitive measures ANOVA followed 
by a Tukey post-hoc test for multiple comparison on the 
Excel and Instat computer programs.  A P-value of P<0.05 
was considered representative of a significant difference.
3  Results
3.1  Effects on active avoidance test
The control group of rats (saline) showed an increased 
number of conditioned responses (avoidances) on the 3rd, 
4th, and 5th days of learning sessions and on the memory 
retention session of the 12th day (P<0.05), when compared 
to 1st day. The animals treated with scopolamine (model 
group) showed decreased number of avoidances (P<0.05) 
on the 3rd, 4th and 5th days’ learning sessions and during 
memory retention testing, compared to respective day 
control. Animals with model treated with rivastigmine 
showed increased number of avoidances on learning 
session (1st to 5th days) and on memory test (P<0.05) com-
pared to the respective day scopolamine group. Rats with 
model treated with memantine also showed increased 
number of avoidances on learning session and on memory 
Figure 1A: Effects of rivastigmine, memantine and combinatory treatment on active avoidance testing in rats with scopolamine-impaired 
memory. 
Abscissa – days of testing; Ordinate – number of conditioned responses (CR; avoidances). OP<0.05 compared to respective day control group 
data; *P<0.05 compared to respective day scopolamine group data; #P<0.05 compared to Day 1 control group data.
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retention test ({<0.05) compared to the respective day of 
model group. Rats with model, treated with rivastigmine 
and memantine also showed increased number of avoid-
ances on learning session and on memory test (P<0.05), 
compared with the respective day model group, but 
express only the tendency to increased it compared to 
rivastigmine or memantine alone groups (Figure 1A). 
The saline group of rats did not show significant 
changes in the number of UCRs (escapes) during any of 
the five learning sessions or during retention testing com-
pared to first day performance. Animals treated with sco-
polamine (model group) made relatively fewer escapes 
during all learning sessions and during retention testing, 
compared to respective day control group. Animals with 
scopolamine model, treated with rivastigmine showed a 
greater number of escapes on the 1st, 2nd and 5th days of 
learning sessions and on the retention test (P<0.05) com-
pared to respective day model group. Rats with model, 
treated with memantine showed an increased number of 
escapes only on the 2nd day of learning sessions (P<0.05) 
when compared to the scopolamine group. Rats with 
model treated with rivastigmine and memantine in com-
bination showed a greater number of escapes on the 1st 
day of learning sessions and on the memory retention test 
(P<0.05) when compared to respective day scopolamine 
group performance (Figure 1B).
Neither the control nor the scopolamine (model) 
groups showed significant changes in the number of 
intertrial crossings during either the learning or memory 
retention test sessions, compared to 1st day of respective 
group. Rats with model, treated with rivastigmine showed 
an increased number of intertrial crossings on the 1st, 3rd, 
4th and 5th days of learning session (P<0.05) and on the 
memory retention test (P<0.01), compared to respective 
day of model group. Rats with model, treated memantine 
showed an increased number of intertrial crossings on the 
4th and 5th days of learning session (P<0.05), compared to 
respective day model group. Animals with model, treated 
with rivastigmine and memantine in combination made a 
greater number of intertrial crossings on the 1st (P<0.01), 
4th and 5th days (P<0.05) of learning session, compared to 
the respective day of model group (Figure 1C).
3.2  Effects on step-through passive 
avoidance tests
The control group of rats showed a prolonged latency 
of reaction (P<0.05) during both short- and long-term 
Figure 1B: Effects of rivastigmine, memantine and combinatory treatment on active avoidance testing in rats with scopolamine-impaired 
memory. 
Abscissa – days of testing; Ordinate – number of unconditioned responses (UCR; escapes). *P<0.05 compared to respective day scopola-
mine group data; 
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memory tests, compared to 1st day learning session. 
Animals in the scopolamine group (model group) showed 
a shortened latency of reaction (P<0.05) on the 1st and 2nd 
learning sessions, compared to respective day of controls. 
Rats with model, treated with rivastigmine do not change 
the latency of reaction on learning and memory retention, 
compared to the respective day of model group. Rats with 
model, treated with memantine, and rats with model, 
treated with the combination of the two (rivastigmine 
and memantine) showed a prolonged latency of reaction 
during the 1st and 2nd days of learning sessions (P<0.05), 
compared to respective day of model group (Figure 2).
3.3  Effects on step-down passive avoidance 
testing
The control group of rats showed a prolonged latency of 
reaction (P<0.05) on the 2nd day of learning and on both 
short- and long-term memory retention tests, compared to 
1st day. Animals with scopolamine (model group) demon-
strated a shortened latency of reaction on two days learn-
ing, short- and long-term memory retention tests (P<0.05), 
compared to those days controls. Animals with model 
treated with rivastigmine showed a prolonged latency 
of reaction on the 1st and 2nd days of learning sessions 
and during short- and long-term memory retention test 
(P<0.05), compared to the same days model group. Rats 
with model treated with memantine showed prolonged 
latency of reaction (P<0.05) on learning and short and 
long memory retention tests, compared to the respective 
days of model group. Rats with model treated with the 
combination showed prolonged latency (P<0.05) on learn-
ing and on short and long memory tests, compared to the 
respective days of model group (Figure 3).
4  Discussion
Our experiments suggest that control rats learned the task 
and keep it during memory tests in both active and passive 
avoidance tests. Rats with scopolamine-induced memory 
impairment failed to perform during learning and memory 
retention sessions of active avoidance test and during 
step-through and step-down passive avoidance tests. 
Rivastigmine improved learning in active avoidance 
testing and performance during memory retention test of 
rats with scopolamine-impaired memory, as evidenced by 
the increases in observed CR and UCR values (Figure1A, 
Figure 1C:  Effects of rivastigmine, memantine and combinatory treatment on active avoidance testing in rats with scopolamine-impaired 
memory. 
Abscissa – days of testing; Ordinate – number of intertrial crossings. *P<0.05 and **P<0.01 compared to respective day scopolamine group 
data; 
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Figure 2:  Effects of rivastigmine, memantine and combinatory treatment on step-through passive avoidance testing in rats with scopola-
mine-impaired memory. 
Abscissa – days of testing; Ordinate – latency of reaction in seconds. OP<0.05 compared to respective day control group data; *P<0.05 com-
pared to the respective day scopolamine group data; #P<0.05 compared to the Day 1 control group data.
Figure 3:  Effects of rivastigmine, memantine and combinatory treatment on step-down passive avoidance testing in rats with scopolamine-
impaired memory. 
Abscissa – days of testing; Ordinate – latency of reaction in seconds. OP<0.05 compared to the respective day control group data; *P<0.05 
compared to the respective day scopolamine group data; #P<0.05 compared to the Day 1 control group data.
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B and C). Rivastigmine also resulted in enhanced perfor-
mance of rats with model of impaired memory in the step-
down passive avoidance test, but do not change it in step-
through test (Figure 2 and Figure 3). 
Generally, rivastigmine enhances cholinergic func-
tion by prolonging the activity of endogenously released 
acetylcholine [1, 12]. There is evidence that an abundance 
of ACh will positively modulate glutamatergic function in 
animal models [2]. In acting on muscarinic receptors, ACh 
enhances the NMDA-mediated component of excitatory 
postsynaptic potentials [13]. Multiple lines of evidence 
suggest, that ACh might influence the excitability of cor-
tical and hippocampal glutamatergic networks [14] and 
plays a prominent role on neocortical excitability through 
complex interactions with glutamatergic pathways.
In the present study, administration of memantine on 
rats with model of amnesia, improved performance during 
learning and memory retention sessions in active avoid-
ance testing, as evidenced by the increase in CR values 
in the data (Figure 1A, B and C). Memantine administra-
tion also improved the latency of reaction during learning 
(step-through) and memory (both step-through and step-
down) sessions (Figure 2 and Figure 3).
It is well known that amyloid-beta peptides (Aβ) 
observed in AD can trigger apoptotic cascades in neurons. 
Miguel-Hidalgo JJ et al, [15] found that memantine, an 
uncompetitive antagonist of NMDA receptors approved for 
the treatment of moderate to severe Alzheimer’s disease, 
can prevent neurodegeneration induced by intracranial 
Aβ (1-40) injection. The study hypothesized that meman-
tine would prevent Aβ (1-40) induced cognitive impair-
ment, neurodegeneration and apoptosis in hippocam-
pal neurons of rats and improve performance in active 
avoidance testing. Based on their results, the authors con-
cluded, that memantine can prevent amyloid-triggered 
expression of apoptosis-related markers and concomitant 
cognitive deficits. Others [16] found, that memantine pre-
vents memory consolidation failure induced by soluble 
beta amyloid in rats.
Our results showed that the administration of rivastig-
mine and memantine in combination on rats with model 
of impaired memory, improved learning and the formation 
of memory in rats during active avoidance tests. The com-
bination treatment also improved performance during the 
learning sessions of step-through testing and during both 
learning and memory retention sessions of step-down 
passive avoidance testing.
Jung JY et al, [17] studied the effects of cholinester-
ase inhibitors donepezil and galanthamine in combi-
nation with the NMDA receptor blocker memantine on 
sleep-wake architecture in rats. The study found that 
the combination of donepezil and memantine induced 
a significant increase in total wake duration as well as a 
decrease in total slow-wave sleep, REM sleep, and delta 
activity. Additionally, it was found that memantine admin-
istration alone increased sleep latency and motor activity. 
Based on these results, it was concluded that cholinester-
ase inhibitors might be useful as anti-dementia drugs that 
do not cause sleep disturbances. Others [18] establish that 
acetylcholinesterase inhibitors galantamine and donepe-
zil, used in small doses fully reversed both methyllycac-
onitine- and scopolamine- induced cognitive dysfunction 
in  mice. 
Alzheimer’s disease is characterized by imbalances 
of various neurotransmitter systems long before the onset 
of symptoms. It has been proposed that a treatment plan 
which enhances both cholinergic and glutamatergic 
systems, implemented at the earliest stages of the disease, 
would be advantageous in counteracting the decline of 
cortical synaptic plasticity [19]. Our results are in favour of 
such hypothesis. The mechanism underlying the synergis-
tic interaction between the two drugs is unclear. There are 
multiple neural substrates that might be involved in this 
interaction. One notable is the hippocampal excitatory 
circuit. This circuit receives tonic excitatory cholinergic 
input from the medial septum and the diagonal band of 
Broca. Glutamate, on the other hand, acts on NMDA recep-
tors located on inhibitory GABAergic interneurons within 
the septum to inhibit the activity of cholinergic neurons 
that project to the hippocampus [12]. Consistent with this 
localization, behaviour and elecrophysiological studies 
have shown that memantine increases cholinergic signal-
ling and excitability in the mouse hippocampus and that 
this action is blocked by the muscarinic antagonist scopol-
amine [20]. Therefore, the memory potentiation observed 
and documented in our study may be due to a choliner-
gic activation resulting from concomitant treatment with 
memantine and rivastigmine, acting through N and M 
cholinergic pathways in accordance with the hypothesis 
of  Busquet et al [21].
Further investigation of the neurochemical alterations 
involved in these key cognitive areas of the brain may lead 
to complex implications about the mechanisms of learn-
ing and memory. One such implication is that the com-
bination of a cholinesterase inhibitor with a glutamate 
antagonist may be a beneficial option for the treatment 
of AD [22]. Perhaps the use of small doses of rivastigmine 
and memantine in a multitargeted approach to treatment 
could overcome some of the major limitations of current 
drug therapies and provide such benefits as increased effi-
cacy and a reduced incidence of adverse drug reactions.
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